Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Clinical trials in humans (1)
- Clinical trials in humans (2)
- VSV-vectored vaccines
- Isolated incidence in DRC
- Likati outbreak 2017
- Setting of the lab
- Timeline of EVD outbreak in Likati
- Transmission chain in Likati 2017
- Recent outbreaks in equator and North Kivu
- North Kivu 2018 (1)
- North Kivu 2018 (2)
- How can the scientific community help?
- Vaccine platform
- Vaccine clinical development timeline
- Vaccine development milestones
- FDA approves first human trial for Zika vaccine
- Synthetic DNA vaccine for Zika in North America
- 2017/18 annual review
- Rapid response
- How can the scientific community contribute better?
- Acknowledgements
Topics Covered
- Specific tools including vaccine and therapeutics to control outbreaks
- Improved non-viral DNA-based and viral VSV-based vaccines
- Recent outbreaks in Likati and North Kivu
- New strategies to rapidly develop novel immune therapies and vaccines
- Applications against Ebola virus and others high consequence pathogens
- Recent findings on rapid vaccination regimens and their promising potential
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Kobinger, G. (2020, February 27). Usage of vaccines and therapeutics in public health emergencies 2 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 11, 2024, from https://doi.org/10.69645/PUOD6100.Export Citation (RIS)
Publication History
Financial Disclosures
- Consultant of Inovio Inc for their program on Lassa DNA vaccine development (not mentioned in the talk but the DNA platform for Zika is included and Inovio is on 2 of the slides to acknowledge their contribution). I have not received financial compensation yet however it is possible that I will this year or next to a maximum of $5000 USD/year.
Usage of vaccines and therapeutics in public health emergencies 2
Published on February 27, 2020
39 min
A selection of talks on Immunology
Transcript
Please wait while the transcript is being prepared...
0:00
Welcome back to the second part of my talk
on usage of vaccines and therapeutics in public health emergencies.
In the second part of this talk,
I will be covering specific tools like vaccine and
therapeutics and mechanism of making
those vaccines and therapeutics focused on Ebola outbreak.
0:21
This long list is actually all the clinical trials that were initiated in humans,
mainly first in North America and Europe,
and then after that in west Africa.
Each one of them is not important per se.
What's important is to show you all the work that was done
about a year and a half at the same time as this outbreak was ongoing,
all the work that was put into having
those clinical trials to make sure that, at the minimum,
the experimental drug and vaccine that were considered were
at least safe and potency could be
tested at the same time could be evaluated but at least there will be
no harm coming from those vaccine and those therapeutics.
1:04
This slide is actually showing how one of the vaccine VSV-Ebola,
was used to try to understand if the vaccine was potent and able to protect people.
So you see a circle where the main individual
in the middle is actually somebody that is found to be positive.
So it's positive for Ebola infection and
the strategy is what's called concentric circles.
So it's to go and offer the vaccine and have
had direct contact with that individual and to
also offer the vaccine to people that have had
contact with the second person if you want.
So it's not only the direct contact,
but it's the contact of the contacts that are offered a vaccine.
So by using this design,
which it wasn't new for the outbreak,
it was a design that was used to eradicate completely
smallpox and the last effort of smallpox vaccination were following the same strategy.
So this was used also for the VSV-Ebola vaccine.
It led to this first paper that associated vaccination with protection in humans.
There was a lot of work that followed this.
First, initial paper and no need to go through all of it,
but just to mention that actually this is the only vaccine and has shown
potency at protecting people against
Ebola infection not because it is the only one working,
but because it is the only one that had the chance to
be in a clinical trial design that had allowed
for the data to really lead to a conclusion of whether or not this vaccine was efficient.
So other vaccine, for example,
there's another Novartis base vaccine that was also evaluated in the phase three trials,
but it did not have that strategy of doing contact and
contact of contact and studied one to vaccinate
the population on the largest scale and hoping that that will
be what's calling attack rates so enough people to get infected to be
able to conclude and compare a population that was vaccinated to
a population that received the placebo or basically a sham vaccine.
Other trials with that lethal virus did not have
enough individual enrolled to lead to any conclusion.
But the good news was that at least one vaccine shown protection in
this outbreak the vaccine VSV.